| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antifungal Agents | 15 | 2020 | 1828 | 2.36 | Why? |
| Aspergillus fumigatus | 7 | 2019 | 239 | 1.90 | Why? |
| Drug Resistance, Fungal | 6 | 2019 | 191 | 1.80 | Why? |
| Aspergillosis | 7 | 2019 | 264 | 1.78 | Why? |
| Voriconazole | 2 | 2019 | 206 | 1.34 | Why? |
| Pneumococcal Vaccines | 2 | 2018 | 571 | 0.96 | Why? |
| Candida albicans | 4 | 2018 | 217 | 0.95 | Why? |
| Invasive Pulmonary Aspergillosis | 5 | 2021 | 634 | 0.89 | Why? |
| Belgium | 15 | 2020 | 2064 | 0.84 | Why? |
| Invasive Fungal Infections | 3 | 2019 | 274 | 0.84 | Why? |
| Biofilms | 4 | 2018 | 304 | 0.75 | Why? |
| Azoles | 2 | 2017 | 185 | 0.74 | Why? |
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2018 | 64 | 0.71 | Why? |
| Lyme Disease | 1 | 2019 | 102 | 0.69 | Why? |
| Candidiasis, Vulvovaginal | 1 | 2017 | 10 | 0.69 | Why? |
| Candidiasis, Invasive | 1 | 2018 | 107 | 0.68 | Why? |
| Candida | 3 | 2018 | 425 | 0.67 | Why? |
| Central Venous Catheters | 1 | 2018 | 188 | 0.64 | Why? |
| Gastric Bypass | 1 | 2018 | 152 | 0.64 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.63 | Why? |
| Streptococcus pneumoniae | 2 | 2018 | 827 | 0.62 | Why? |
| Aspergillus | 5 | 2020 | 347 | 0.61 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.61 | Why? |
| Catheter-Related Infections | 2 | 2018 | 381 | 0.59 | Why? |
| Mycology | 4 | 2021 | 37 | 0.59 | Why? |
| Microbiological Techniques | 1 | 2017 | 232 | 0.57 | Why? |
| Mucous Membrane | 1 | 2017 | 305 | 0.56 | Why? |
| Vagina | 1 | 2017 | 327 | 0.54 | Why? |
| Pharmacies | 1 | 2019 | 356 | 0.54 | Why? |
| RNA, Ribosomal, 16S | 1 | 2017 | 793 | 0.53 | Why? |
| Hematologic Neoplasms | 4 | 2019 | 2105 | 0.49 | Why? |
| Endocarditis, Bacterial | 1 | 2017 | 344 | 0.47 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.46 | Why? |
| Standard of Care | 1 | 2019 | 1297 | 0.46 | Why? |
| Fungemia | 1 | 2012 | 86 | 0.46 | Why? |
| Microbial Sensitivity Tests | 9 | 2019 | 2886 | 0.43 | Why? |
| Fluconazole | 3 | 2018 | 145 | 0.37 | Why? |
| Polymerase Chain Reaction | 3 | 2017 | 6740 | 0.35 | Why? |
| Pulmonary Aspergillosis | 2 | 2021 | 408 | 0.29 | Why? |
| Immunization Programs | 1 | 2018 | 2006 | 0.29 | Why? |
| Anti-Infective Agents | 1 | 2017 | 1766 | 0.29 | Why? |
| Pneumocystis carinii | 2 | 2017 | 205 | 0.28 | Why? |
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 2426 | 0.28 | Why? |
| Molecular Diagnostic Techniques | 3 | 2019 | 4239 | 0.28 | Why? |
| Fungal Proteins | 3 | 2019 | 133 | 0.27 | Why? |
| Surgical Wound Infection | 2 | 2019 | 501 | 0.26 | Why? |
| Pneumonia, Pneumocystis | 2 | 2017 | 322 | 0.24 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.24 | Why? |
| Mycoses | 2 | 2019 | 589 | 0.23 | Why? |
| Bacteremia | 1 | 2012 | 1372 | 0.22 | Why? |
| Medical Order Entry Systems | 1 | 2020 | 43 | 0.21 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.21 | Why? |
| Clinical Laboratory Information Systems | 1 | 2020 | 66 | 0.21 | Why? |
| Bronchoalveolar Lavage Fluid | 3 | 2020 | 2309 | 0.21 | Why? |
| Echinocandins | 2 | 2018 | 139 | 0.20 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.20 | Why? |
| Human Body | 1 | 2018 | 23 | 0.19 | Why? |
| Anastomotic Leak | 1 | 2018 | 46 | 0.19 | Why? |
| Nod2 Signaling Adaptor Protein | 1 | 2018 | 39 | 0.19 | Why? |
| Hantavirus Infections | 1 | 2019 | 62 | 0.18 | Why? |
| Intestinal Fistula | 1 | 2018 | 43 | 0.18 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2019 | 144 | 0.18 | Why? |
| Candida glabrata | 1 | 2018 | 50 | 0.18 | Why? |
| Phosphorylcholine | 1 | 2017 | 15 | 0.18 | Why? |
| Biological Assay | 2 | 2018 | 367 | 0.18 | Why? |
| Transplantation | 1 | 2018 | 72 | 0.18 | Why? |
| Chromatography, Affinity | 1 | 2020 | 310 | 0.18 | Why? |
| Leptospirosis | 1 | 2019 | 103 | 0.18 | Why? |
| Neutrophil Activation | 1 | 2021 | 510 | 0.18 | Why? |
| Quinazolines | 1 | 2019 | 126 | 0.17 | Why? |
| Kuwait | 1 | 2018 | 306 | 0.17 | Why? |
| DNA, Fungal | 1 | 2017 | 95 | 0.17 | Why? |
| Cryptococcus neoformans | 1 | 2018 | 71 | 0.17 | Why? |
| Candidiasis, Oral | 1 | 2017 | 58 | 0.17 | Why? |
| Whole Body Imaging | 1 | 2018 | 116 | 0.17 | Why? |
| Acetates | 1 | 2019 | 123 | 0.17 | Why? |
| West Nile virus | 1 | 2018 | 206 | 0.17 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2019 | 8843 | 0.16 | Why? |
| Ileum | 1 | 2018 | 233 | 0.16 | Why? |
| Cryptococcosis | 1 | 2018 | 97 | 0.16 | Why? |
| Treponema pallidum | 1 | 2016 | 42 | 0.16 | Why? |
| Serum | 1 | 2018 | 294 | 0.16 | Why? |
| West Nile Fever | 1 | 2018 | 166 | 0.16 | Why? |
| Glucocorticoids | 1 | 2012 | 4431 | 0.16 | Why? |
| Doxycycline | 1 | 2019 | 307 | 0.16 | Why? |
| Leukopenia | 1 | 2018 | 280 | 0.16 | Why? |
| Hemagglutination Tests | 1 | 2016 | 124 | 0.16 | Why? |
| Intestinal Perforation | 1 | 2018 | 178 | 0.16 | Why? |
| Peritonitis | 1 | 2018 | 217 | 0.16 | Why? |
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.15 | Why? |
| Disease Resistance | 1 | 2018 | 236 | 0.15 | Why? |
| Nucleocapsid | 1 | 2021 | 734 | 0.15 | Why? |
| Syphilis | 2 | 2018 | 318 | 0.15 | Why? |
| Encephalitis Viruses, Tick-Borne | 1 | 2016 | 100 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2019 | 399 | 0.15 | Why? |
| Laboratories, Hospital | 1 | 2020 | 489 | 0.15 | Why? |
| Encephalitis, Tick-Borne | 1 | 2016 | 86 | 0.15 | Why? |
| Lymphoma | 1 | 2020 | 522 | 0.15 | Why? |
| Foreign Bodies | 1 | 2018 | 171 | 0.15 | Why? |
| Mice, Inbred BALB C | 4 | 2018 | 5814 | 0.15 | Why? |
| Galactose | 3 | 2020 | 201 | 0.14 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.14 | Why? |
| Plasmids | 1 | 2018 | 840 | 0.14 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.14 | Why? |
| Bacteriological Techniques | 2 | 2016 | 239 | 0.14 | Why? |
| DNA Primers | 1 | 2019 | 1170 | 0.13 | Why? |
| Heat-Shock Proteins | 1 | 2017 | 226 | 0.13 | Why? |
| Mannans | 3 | 2020 | 218 | 0.13 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.13 | Why? |
| Multimodal Imaging | 1 | 2018 | 534 | 0.13 | Why? |
| Triazoles | 1 | 2018 | 440 | 0.13 | Why? |
| Clinical Laboratory Techniques | 5 | 2020 | 23402 | 0.13 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Cytomegalovirus | 1 | 2019 | 600 | 0.13 | Why? |
| Bronchiectasis | 1 | 2018 | 312 | 0.13 | Why? |
| Humans | 52 | 2021 | 930598 | 0.13 | Why? |
| Fractures, Bone | 1 | 2019 | 487 | 0.13 | Why? |
| Hematologic Diseases | 1 | 2020 | 614 | 0.13 | Why? |
| DNA, Bacterial | 1 | 2017 | 835 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.12 | Why? |
| Luminescent Measurements | 1 | 2018 | 924 | 0.12 | Why? |
| Influenza B virus | 1 | 2018 | 815 | 0.12 | Why? |
| Cytomegalovirus Infections | 1 | 2019 | 667 | 0.12 | Why? |
| Hematology | 1 | 2019 | 649 | 0.12 | Why? |
| Retrospective Studies | 13 | 2021 | 105322 | 0.12 | Why? |
| Clostridium Infections | 1 | 2019 | 595 | 0.11 | Why? |
| Patient Transfer | 1 | 2018 | 898 | 0.11 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.11 | Why? |
| Maternal Health Services | 1 | 2020 | 808 | 0.11 | Why? |
| Female | 25 | 2021 | 380317 | 0.11 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.11 | Why? |
| Enterovirus | 1 | 2014 | 402 | 0.10 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2017 | 846 | 0.10 | Why? |
| Interleukin-10 | 1 | 2017 | 1409 | 0.10 | Why? |
| Infant, Newborn | 4 | 2020 | 23105 | 0.10 | Why? |
| Bacteria | 2 | 2019 | 1897 | 0.10 | Why? |
| Encephalitis, Viral | 1 | 2014 | 355 | 0.10 | Why? |
| Bronchoscopy | 1 | 2018 | 991 | 0.10 | Why? |
| Mucormycosis | 1 | 2019 | 832 | 0.10 | Why? |
| Sputum | 1 | 2018 | 1720 | 0.10 | Why? |
| Enterovirus Infections | 1 | 2014 | 404 | 0.10 | Why? |
| Male | 22 | 2021 | 367725 | 0.10 | Why? |
| Congresses as Topic | 1 | 2019 | 1347 | 0.09 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.09 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.09 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.09 | Why? |
| Aged | 16 | 2021 | 215776 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.09 | Why? |
| Guideline Adherence | 2 | 2019 | 2309 | 0.09 | Why? |
| Practice Guidelines as Topic | 5 | 2019 | 15421 | 0.09 | Why? |
| Graft vs Host Disease | 1 | 2012 | 501 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Immunoassay | 3 | 2020 | 4485 | 0.09 | Why? |
| Epidemiological Monitoring | 2 | 2018 | 3493 | 0.09 | Why? |
| Tertiary Care Centers | 2 | 2017 | 8248 | 0.09 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2017 | 1234 | 0.09 | Why? |
| Immune Evasion | 1 | 2018 | 2081 | 0.08 | Why? |
| Antibodies, Viral | 7 | 2021 | 51949 | 0.08 | Why? |
| Antineoplastic Agents | 2 | 2014 | 3550 | 0.08 | Why? |
| Incidence | 4 | 2019 | 25622 | 0.08 | Why? |
| Aged, 80 and over | 8 | 2020 | 88759 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Sensitivity and Specificity | 7 | 2021 | 22971 | 0.08 | Why? |
| Infant | 3 | 2018 | 30274 | 0.08 | Why? |
| Influenza A virus | 1 | 2018 | 2234 | 0.08 | Why? |
| Disease Models, Animal | 3 | 2018 | 10998 | 0.08 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.08 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2019 | 6551 | 0.07 | Why? |
| Influenza, Human | 2 | 2020 | 10779 | 0.07 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.07 | Why? |
| Mice | 3 | 2018 | 21357 | 0.07 | Why? |
| Candidiasis | 2 | 2018 | 334 | 0.07 | Why? |
| Adult | 13 | 2020 | 244371 | 0.07 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.06 | Why? |
| Child, Preschool | 3 | 2017 | 36283 | 0.06 | Why? |
| Antigens, Viral | 1 | 2020 | 6298 | 0.06 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.06 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.06 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.06 | Why? |
| Genetic Predisposition to Disease | 1 | 2017 | 4027 | 0.06 | Why? |
| Mutation | 2 | 2019 | 12376 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Inflammatory Bowel Diseases | 1 | 2019 | 3209 | 0.06 | Why? |
| Meaningful Use | 1 | 2020 | 25 | 0.06 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.05 | Why? |
| Treatment Outcome | 5 | 2019 | 51732 | 0.05 | Why? |
| Lung | 3 | 2018 | 31049 | 0.05 | Why? |
| Antigen-Presenting Cells | 1 | 2021 | 206 | 0.05 | Why? |
| Europe | 4 | 2018 | 12702 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.05 | Why? |
| Viruses | 1 | 2014 | 2238 | 0.05 | Why? |
| Animals | 6 | 2018 | 78931 | 0.05 | Why? |
| Meningism | 1 | 2019 | 5 | 0.05 | Why? |
| Puumala virus | 1 | 2019 | 11 | 0.05 | Why? |
| Photophobia | 1 | 2019 | 14 | 0.05 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.05 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.05 | Why? |
| Nucleic Acid Synthesis Inhibitors | 1 | 2019 | 43 | 0.05 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.05 | Why? |
| Hyperbilirubinemia | 1 | 2019 | 81 | 0.05 | Why? |
| Drug Evaluation | 1 | 2019 | 100 | 0.05 | Why? |
| Plankton | 1 | 2017 | 8 | 0.05 | Why? |
| Histocompatibility Antigens Class II | 1 | 2021 | 383 | 0.05 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Optical Fibers | 1 | 2018 | 35 | 0.04 | Why? |
| Netherlands | 2 | 2018 | 3533 | 0.04 | Why? |
| Enterobacter cloacae | 1 | 2018 | 58 | 0.04 | Why? |
| Endodeoxyribonucleases | 1 | 2019 | 149 | 0.04 | Why? |
| Reverse Transcription | 1 | 2021 | 673 | 0.04 | Why? |
| Microscopy, Electron, Scanning | 1 | 2018 | 221 | 0.04 | Why? |
| Child | 3 | 2017 | 70012 | 0.04 | Why? |
| Fracture Fixation | 1 | 2019 | 128 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2018 | 5542 | 0.04 | Why? |
| Microscopy, Fluorescence | 1 | 2018 | 335 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Hungary | 1 | 2018 | 491 | 0.04 | Why? |
| Leukocytosis | 1 | 2019 | 280 | 0.04 | Why? |
| Microsatellite Repeats | 1 | 2017 | 99 | 0.04 | Why? |
| Adolescent | 3 | 2017 | 86841 | 0.04 | Why? |
| Benchmarking | 1 | 2020 | 627 | 0.04 | Why? |
| Microscopy, Confocal | 1 | 2018 | 343 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| Phagocytosis | 1 | 2018 | 409 | 0.04 | Why? |
| Paranasal Sinuses | 1 | 2018 | 217 | 0.04 | Why? |
| Bilirubin | 1 | 2019 | 503 | 0.04 | Why? |
| APACHE | 1 | 2018 | 682 | 0.04 | Why? |
| Prognosis | 1 | 2019 | 32490 | 0.04 | Why? |
| Amphotericin B | 1 | 2017 | 256 | 0.04 | Why? |
| Prosthesis-Related Infections | 1 | 2019 | 302 | 0.04 | Why? |
| Proteinuria | 1 | 2019 | 474 | 0.04 | Why? |
| Lectins, C-Type | 1 | 2018 | 405 | 0.04 | Why? |
| Drug Synergism | 1 | 2018 | 833 | 0.04 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.04 | Why? |
| Fungi | 1 | 2018 | 471 | 0.04 | Why? |
| Rats, Sprague-Dawley | 1 | 2017 | 987 | 0.03 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.03 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.03 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.03 | Why? |
| RNA, Viral | 2 | 2019 | 32276 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2020 | 25288 | 0.03 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.03 | Why? |
| Phylogeography | 1 | 2017 | 824 | 0.03 | Why? |
| Myalgia | 1 | 2019 | 1015 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2014 | 6817 | 0.03 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.03 | Why? |
| Creatinine | 1 | 2019 | 1443 | 0.03 | Why? |
| Respiration | 1 | 2018 | 729 | 0.03 | Why? |
| Extracellular Traps | 1 | 2021 | 1036 | 0.03 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 9335 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2019 | 1083 | 0.03 | Why? |
| Klebsiella pneumoniae | 1 | 2018 | 658 | 0.03 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.03 | Why? |
| Environment | 1 | 2018 | 769 | 0.03 | Why? |
| Stem Cell Transplantation | 1 | 2017 | 531 | 0.03 | Why? |
| Drug Interactions | 1 | 2019 | 1653 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2019 | 1995 | 0.03 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2014 | 403 | 0.03 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.03 | Why? |
| Biopsy | 1 | 2019 | 2811 | 0.03 | Why? |
| Rats | 1 | 2017 | 2764 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.03 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Antimicrobial Stewardship | 1 | 2018 | 931 | 0.02 | Why? |
| Phylogeny | 2 | 2018 | 13341 | 0.02 | Why? |
| Staphylococcal Infections | 1 | 2018 | 1099 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2020 | 2643 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Headache | 1 | 2019 | 2257 | 0.02 | Why? |
| Outpatients | 1 | 2021 | 3417 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.02 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2020 | 3228 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2016 | 2149 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.02 | Why? |
| Antiviral Agents | 1 | 2019 | 41703 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.02 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Leadership | 1 | 2018 | 2241 | 0.02 | Why? |
| Seasons | 1 | 2017 | 4071 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2019 | 7220 | 0.02 | Why? |
| Pandemics | 6 | 2020 | 389249 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 1573 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| Genetic Variation | 1 | 2017 | 3919 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2019 | 5150 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2019 | 7972 | 0.01 | Why? |
| Transplant Recipients | 1 | 2019 | 4982 | 0.01 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.01 | Why? |
| Immunoglobulins, Intravenous | 1 | 2014 | 2705 | 0.01 | Why? |
| Fever | 1 | 2019 | 7795 | 0.01 | Why? |
| Patient Admission | 1 | 2018 | 5250 | 0.01 | Why? |
| Registries | 1 | 2021 | 12327 | 0.01 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2018 | 6537 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Genome, Viral | 1 | 2018 | 13157 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2019 | 25144 | 0.01 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.01 | Why? |